Whitmer, R, Sidney, S, Selby, J, Johnston, SC, Yaffe, K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology
2005; 64: 277–81.
Rozzini, L, Chilovi, BV, Bertoletti, E, Conti, M, Del Rio, I, Trabucchi, M, et al Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int J Geriatr Psychiatry
2006; 21: 550–5.
Hajjar, I, Hart, M, Chen, YL, Mack, W, Novak, V, Chui, CH, et al Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial. J Am Geriatr Soc
2013; 61: 194–201.
Gao, Y, O'Caoimh, R, Healy, L, Kerins, DM, Eustace, J, Guyatt, G, et al Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia. BMJ Open
2013; 3: e002881.
Skoog, I. The relationship between blood pressure and dementia: a review. Biomed Pharmacother
1997; 51: 367–75.
Hanon, O, Seux, ML, Lenoir, H, Rigaud, AS, Forette, F. Hypertension and dementia. Curr Cardiol Rep
2003; 5: 435–40.
Launer, LJ, Ross, GW, Petrovitch, H, Masaki, K, Foley, D, White, LR, et al Midlife blood pressure and dementia: The Honolulu-Asia aging study. Neurobiol Aging
2000; 21: 49–55.
Poon, IO. Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment. Pharmacotherapy
2008; 28: 366–75.
De Oliveira, FF, Bertolucci, PH, Chen, ES, Smith, MC. Brain-penetrating angiotensin-converting enzyme inhibitors and cognitive change in patients with dementia due to Alzheimer's disease. J Alzheimers Dis
2014; 42 (suppl 3): S321–4.
Ohrui, T, Tomita, N, Sato-Nakagawa, T, Matsui, T, Maruyama, M, Niwa, K, et al Effects of brain penetrating ACE inhibitors on Alzheimer disease progression. Neurology
2004; 63: 1324–5.
Sink, KM, Leng, X, Williamson, J, Kritchevsky, SB, Yaffe, K, Kuller, L, et al Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. J. Arch Intern Med
2009; 169: 1195–202.
Hebert, PL, McBean, AM, O'Connor, H, Frank, B, Good, C, Maciejewski, ML. Time until incident dementia among Medicare beneficiaries using centrally acting or non-centrally acting ACE inhibitors. Pharmacoepidemiol Drug Saf
2013; 22: 641–8.
Ohrui, T, Matsui, T, Yamaya, M, Arai, H, Ebihara, S, Maruyama, M, et al Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan. J Am Geriatr Soc
2004; 52: 649–50.
Li, NC, Lee, A, Whitmer, RA, Kivipelto, M, Lawler, E, Kazis, LE, et al Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ
2010; 340: b5465.
Maxwell, CJ, Hogan, DB. Antihypertensive agents and prevention of dementia. BMJ
2010; 340: b5409.
Opie, LH. Inhibition of the cerebral renin–angiotensin system to limit cognitive decline in elderly hypertensive persons. Cardiovasc Drugs Ther
2011; 25: 277–9.
Fernandes, AC, Cloete, D, Broadbent, MTM, Hayes, RD, Chang, C-K, Roberts, A, et al Development and evaluation of a de-identification procedure for a case register sourced from mental health electronic records. BMC Med Inform Decis Mak
2013; 13: 71.
Stewart, R, Soremekun, M, Perera, G, Broadbent, M, Callard, F, Denis, M, et al The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) Case Register: development and descriptive data. BMC Psychiatry
2009; 9: 51.
Hayes, RD, Chang, C-K, Fernandes, A, Broadbent, M, Lee, W, Hotopf, M, et al Associations between substance use disorder sub-groups, life expectancy and all-cause mortality in a large British specialist mental healthcare service. Drug Alcohol Depend
2011; 118: 56–61.
Chang, C-K, Hayes, RD, Perera, G, Broadbent, MTM, Fernandes, AC, Lee, WE, et al Life expectancy at birth for people with serious mental illness from a secondary mental health care case register in London, UK. PLoS One
2010; 6: e19590.
Perera, G, Khondoker, M, Broadbent, M, Breen, G, Stewart, R. Factors associated with response to acetylcholinesterase inhibition in dementia: a cohort study from a secondary mental health case register in London. PLoS One
2014; 9: e109484.
Sultana, J, Chang, C-K, Hayes, RD, Broadbent, M, Stewart, R, Corbett, A, et al Associations between risk of mortality and atypical antipsychotic use in vascular dementia: a clinical cohort study. Int J Geriatr Psychiatry
2014; 29: 1249–54.
Ward, G, Perera, G, Stewart, R. Predictors of mortality for people aged over 65 years receiving mental healthcare for delirium, in a south London Mental Health Trust, UK: a retrospective survival analysis. Int J Geriatr Psychiatry
2015; 30: 639–46.
Perera, G, Broadbent, M, Callard, F, Chang, C-K, Downs, J, Dutta, R, et al Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record derived data resource. BMJ Open
2016; 6: e008721.
Folstein, MF, Folstein, SE, McHugh, PR. Mini-Mental State: a practical method for grading the cognitive state of patients for clinicians. J Psychiatr Res
1975; 12: 189–98.
Rigby, RA, Stasinopoulos, DM. Generalized additive models for location, scale and shape. Appl Stat
2005; 54; 507–54.
Tzourio, C, Anderson, C, Chapman, N, Woodward, M, Neal, B, MacMahon, S, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med
2003; 163: 1069–75.
O'Caoimh, R, Healy, L, Gao, Y, Svendrovski, A, Kerins, DM, Eustace, J, et al Effects of centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer's disease. J Alzheimers Dis
2014; 40: 595–603.
Kehoe, PG, Davies, NM, Martin, RM, Ben-Shlomo, Y. Angiotensin targeting antihypertensive drugs with mortality and hospitalization in primary care patients with dementia. J Alzheimers Dis
2013; 33: 999–1008.
Zou, K, Liu, J, Watanabe, A, Hiraga, S, Liu, S, Tanabe, C, et al Abeta43 is the earliest-depositing Abeta species in APP transgenic mouse brain and is converted to Abeta41 by two active domains of ACE. Am J Pathol
2013; 182: 2322–31.
Ruitenberg, A, den Heijer, T, Bakker, SL, van Swieten, JC, Koudstaal, PJ, Hofman, A, et al Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol
2005; 57: 789–94.
Savaskan, E, Hock, C, Olivieri, G, Bruttel, S, Rosenberg, C, Hulette, C, et al Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging
2001; 22: 541–6.
Wright, JW, Reichert, JR, Davis, CJ, Harding, JW. Neural plasticity and the brain renin-angiotensin system. Neurosci Biobehav Rev
2002; 26: 529–52.
Tuppo, EE, Arias, HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol
2005; 37: 289–305.
Yaffe, K, Lindquist, K, Penninx, BW, Simonsick, EM, Pahor, M, Kritchevsky, S, et al Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology
2003; 61: 76–80.
Xue, B, Zhang, Z, Roncari, CF, Guo, F, Johnson, AK. Aldosterone acting through the central nervous system sensitizes angiotensin II-induced hypertension. Hypertension
2012; 60: 1023–30.
Wright, JW, Kawas, LH, Harding, JW. A role for the brain RAS in Alzheimer's and Parkinson's diseases. Front Endocrinol (Lausanne)
2013; 4: 158.
Dong, YF, Kataoka, K, Tokutomi, Y, Nako, H, Nakamura, T, Toyama, K, et al Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease. FASEB J
2011; 25: 2911–20.
Tota, S, Nath, C, Najmi, AK, Shukla, R, Hanif, K. Inhibition of central angiotensin converting enzyme ameliorates scopolamine induced memory impairment in mice: role of cholinergic neurotransmission, cerebral blood flow and brain energy metabolism. Behav Brain Res
2012; 232: 66–76.
Wyss, JM, Kadish, I, van Groen, T. Age-related decline in spatial learning and memory: attenuation by captopril. Clin Exp Hypertens
2003; 25: 455–74.
Barnes, JM, Barnes, NM, Costall, B, Horovitz, ZP, Ironside, JW, Naylor, RJ, et al Angiotensin II inhibits cortical cholinergic function: implications for cognition. J Cardiovasc Pharmacol
1990; 16: 234–8.
Yamada, K, Horita, T, Takayama, M, Takahashi, S, Takaba, K, Nagata, Y, et al Effect of a centrally active angiotensin converting enzyme inhibitor, perindopril, on cognitive performance in chronic cerebral hypo-perfusion rats. Brain Res
2011; 1421: 110–20.
Ferrari, R, Boersma, E. The impact of ACE inhibition on all-cause and cardiovascular mortality in contemporary hypertension trials: a review. Expert Rev Cardiovasc Ther
2013; 11: 705–17.
Rygiel, K. Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer's disease? An overview of research evidence in the elderly patient population. J Postgrad Med
2016; 62: 242–8.